Clottability-Based Personalized Treatment System for Anticoagulant Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant drug prescriptions for thrombosis prevention are empirical and lack individual specificity, leading to increased risks of life-threatening thrombosis or bleeding, as they do not account for patient-specific variability in immune and blood coagulation systems.
Innovation Solution
A method utilizing a novel clottability biomarker determined by multiple assays in blood samples, combined with patient background information, to classify and personalize anticoagulant treatment regimens, thereby reducing the risk of thrombosis and bleeding by providing precise dosage adjustments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If empirical anticoagulant prescriptions are used based on population studies, then treatment coverage is broad, but individual treatment precision is poor leading to increased risks of thrombosis or bleeding
Solution Approach 1:
The patent changes the parameter basis for treatment from population-averaged PT/INR values to individual-specific clottability biomarker values. By measuring and modeling each patient's unique clottability parameter, the system enables personalized anticoagulant dosing that adapts to individual variability in immune and coagulation systems, thereby improving individual treatment precision while maintaining broad applicability through the universal clottability measurement approach
Solution Approach 2:
The patent implements a feedback mechanism where clottability biomarker measurements are continuously taken from patient blood samples, compared against personalized target ranges, and used to adjust subsequent anticoagulant dosing decisions. This closed-loop feedback system allows dynamic adaptation of treatment to each patient's real-time coagulation status, resolving the contradiction between broad treatment coverage and individual precision
2Ease of operation
If standardized PT/INR clotting assays are used for dosage determination, then dosing procedure is simple, but individual variability in biochemical and physiological properties is not captured
Solution Approach 1:
The patent introduces a computational modeling intermediary that bridges the simple PT/INR measurement and the complex individual variability. The system uses machine learning models trained on population data to infer individual biochemical and physiological properties from routine clotting assay results, thereby capturing individual information without requiring complex measurements or procedures
Solution Approach 2:
The patent replaces the mechanical/chemical complexity of direct individualized biochemical measurements with a computational information processing system. Instead of performing complex individualized physiological assessments, the system uses algorithms to extract individual variability information from standardized assays, maintaining procedural simplicity while recovering lost individual information
3Adaptability or versatility
If arbitrary treatment approaches are used despite extended clotting processes, then treatment flexibility is high, but treatment efficacy is poor as thrombosis still occurs
Solution Approach 1:
The patent transforms static arbitrary treatment decisions into dynamic, data-driven dosing adjustments. By continuously monitoring clottability biomarkers and updating personalized target ranges based on treatment response, the system adapts dosing strategies in real-time to each patient's changing coagulation status, thereby maintaining treatment flexibility while significantly improving efficacy through evidence-based adjustments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for patient-specific anticoagulant and anti-bleeding treatment, reducing the risk of thrombosis and bleeding by offering personalized and precise dosage adjustments based on individual coagulation system activity, improving treatment efficacy and reducing side effects.
Implementation Method 1
the coagulation system, which transforms soluble fibrinogen into insoluble fibrin and thus forms a clot
Data Source
AI summary
The present invention provides a method for modelling clottability of a blood sample, comprising determining clottability of blood samples or providing blood samples with known clottability due to the direct effects of biological activities of immune and blood coagulation systems on clottability; determining and attributing a health status and risk factor for thrombosis and/or bleeding to the donor having provided the respective sample; determining the pharmacodynamic effect(s) of one or more drug(s) including anti-inflammatory, anticoagulant(s) and the corresponding therapeutic range(s) on the blood sample to reduce inflammation and/or the risk(s) of thrombosis and/or bleeding; and modelling the clottability of a blood sample after administering the most effective therapeutic strategy involving drugs including anticoagulant to said blood sample.